A Single-Center, Open-Label, Crossover, Randomized Study to Investigate the Impact of the Transdermal Contraceptive Patch Containing 0.55 mg Ethinylestradiol and 2.1 mg Gestodene (Material no. 80876395) in a 21-Day Regimen as Compared to a Monophasic Contraceptive Containing Ethinylestradiol and Levonorgestrel (0.03mg/0.15mg) in a 21-Day Regimen on Hemostatic Parameters in 30 Women Aged 18 182 35 Years Over 3 Treatment Cycles in Each Period.
Phase of Trial: Phase II
Latest Information Update: 11 Sep 2014
At a glance
- Drugs Ethinylestradiol/gestodene (Primary) ; Ethinylestradiol/levonorgestrel
- Indications Pregnancy
- Focus Pharmacodynamics
- Sponsors Bayer
- 17 Sep 2013 Results published in Drugs in R and D.
- 04 Oct 2010 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.
- 04 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History